<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02329535</url>
  </required_header>
  <id_info>
    <org_study_id>EMC-005413-CTIL</org_study_id>
    <nct_id>NCT02329535</nct_id>
  </id_info>
  <brief_title>Comparing Double Dose of Vaginal Progesterone to no Treatment for Prevention of Preterm Birth in Twins and Short Cervix</brief_title>
  <official_title>Comparing a Double Dose of Vaginal Progesterone to no Treatment for the Prevention of Preterm Birth in Twins Pregnancy and Short Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HaEmek Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HaEmek Medical Center, Israel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Twin pregnancies are more likely to be delivered preterm than singleton pregnancies. Vaginal
      progesterone administration (200 mg Utrogestan) to asymptomatic women with a singleton
      pregnancy and sonographic short cervix reduced the risk of preterm birth (PTB) and neonatal
      morbidity and mortality, yet not proved efficient in twins' pregnancy. The investigators'
      hypothesis is that a higher dose of vaginal micronized progesterone will be more effective in
      preventing PTD. The objectives of the study is to compare the rate of preterm birth and
      perinatal morbidity and mortality in a twin pregnancy with short cervical length treated with
      vaginal 400 mg of micronized progesterone to no treatment. The study is Randomized, open
      label, of twin pregnancy between 16-26 weeks of gestation with cervical length under 25 mm.
      Women will be randomly assigned to either treatment or no treatment group. Progesterone
      treatment will be given until 36 weeks of gestation. Other management will be according to
      standard protocol.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Results from similar research were already published
  </why_stopped>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preterm delivery</measure>
    <time_frame>up to 25 weeks from randomization</time_frame>
    <description>Rate of preterm delivery before 37.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Premature Birth</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with 400 mg Micronized progesterone (Utrogestan) daily up to 6 weeks of geastation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment. Regular follow up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micronized progesterone</intervention_name>
    <description>vaginal caps 400 mg daily up to 36 weeks of gestation</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>Utrogestan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Twin gestation

          -  Certain dating (documented first trimester ultrasound, or a reliable menstrual date
             confirmed by an ultrasound performed before 20 weeks of gestation)

          -  Age &gt; 18 years

          -  Gestational age 16-26

          -  Cervical length&lt;25 mm

          -  Intact membranes

          -  Informed consent

        Exclusion Criteria:

          -  Major malformation or chromosomal abnormality to at least one fetus

          -  Higher order pregnancy

          -  Mocochorional-monoamniotic twin

          -  Death of one fetus

          -  Cervical dilatation &gt;3 cm

          -  Chronic medical conditions that would interfere with study participation or evaluation
             of the treatment (e.g. seizures, psychiatric disorders, uncontrolled chronic
             hypertension, congestive heart failure, chronic renal failure, uncontrolled diabetes
             mellitus with end-organ dysfunction, active thrombophlebitis or a thromboembolic
             disorder, history of hormone-associated thrombophlebitis or thromboembolic disorders,
             active liver dysfunction or disease, known or suspected malignancy of the breast or
             genital organs)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raed Salim, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of delivery room, Department of OB-GYN, Emek medical center, Afula, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haemek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Nazareth hospital</name>
      <address>
        <city>Nazareth</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Vayssière C, Favre R, Audibert F, Chauvet MP, Gaucherand P, Tardif D, Grangé G, Novoa A, Descamps P, Perdu M, Andrini E, Janse-Marec J, Maillard F, Nisand I. Cervical length and funneling at 22 and 27 weeks to predict spontaneous birth before 32 weeks in twin pregnancies: a French prospective multicenter study. Am J Obstet Gynecol. 2002 Dec;187(6):1596-604.</citation>
    <PMID>12501070</PMID>
  </reference>
  <reference>
    <citation>Skentou C, Souka AP, To MS, Liao AW, Nicolaides KH. Prediction of preterm delivery in twins by cervical assessment at 23 weeks. Ultrasound Obstet Gynecol. 2001 Jan;17(1):7-10.</citation>
    <PMID>11244660</PMID>
  </reference>
  <reference>
    <citation>Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O'Brien JM, Cetingoz E, Da Fonseca E, Creasy GW, Klein K, Rode L, Soma-Pillay P, Fusey S, Cam C, Alfirevic Z, Hassan SS. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol. 2012 Feb;206(2):124.e1-19. doi: 10.1016/j.ajog.2011.12.003. Epub 2011 Dec 11. Review.</citation>
    <PMID>22284156</PMID>
  </reference>
  <reference>
    <citation>DeFranco EA, O'Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, Soma-Pillay P, Porter K, How H, Schakis R, Eller D, Trivedi Y, Vanburen G, Khandelwal M, Trofatter K, Vidyadhari D, Vijayaraghavan J, Weeks J, Dattel B, Newton E, Chazotte C, Valenzuela G, Calda P, Bsharat M, Creasy GW. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007 Oct;30(5):697-705.</citation>
    <PMID>17899571</PMID>
  </reference>
  <reference>
    <citation>Serra V, Perales A, Meseguer J, Parrilla JJ, Lara C, Bellver J, Grifol R, Alcover I, Sala M, Martínez-Escoriza JC, Pellicer A. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double-blind multicentre trial. BJOG. 2013 Jan;120(1):50-7. doi: 10.1111/j.1471-0528.2012.03448.x. Epub 2012 Aug 13.</citation>
    <PMID>22882759</PMID>
  </reference>
  <reference>
    <citation>Senat MV, Porcher R, Winer N, Vayssière C, Deruelle P, Capelle M, Bretelle F, Perrotin F, Laurent Y, Connan L, Langer B, Mantel A, Azimi S, Rozenberg P; Groupe de Recherche en Obstétrique et Gynécologie. Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. Am J Obstet Gynecol. 2013 Mar;208(3):194.e1-8. doi: 10.1016/j.ajog.2013.01.032.</citation>
    <PMID>23433324</PMID>
  </reference>
  <reference>
    <citation>To MS, Fonseca EB, Molina FS, Cacho AM, Nicolaides KH. Maternal characteristics and cervical length in the prediction of spontaneous early preterm delivery in twins. Am J Obstet Gynecol. 2006 May;194(5):1360-5. Epub 2006 Apr 21.</citation>
    <PMID>16647922</PMID>
  </reference>
  <reference>
    <citation>Rode L, Klein K, Nicolaides KH, Krampl-Bettelheim E, Tabor A; PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol. 2011 Sep;38(3):272-80. doi: 10.1002/uog.9093.</citation>
    <PMID>21739497</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2014</study_first_submitted>
  <study_first_submitted_qc>December 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2014</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>HaEmek Medical Center, Israel</investigator_affiliation>
    <investigator_full_name>Noah Zafran</investigator_full_name>
    <investigator_title>Senion physician OB-GYN</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

